CENTURY THERAPEUTICS INC (IPSC)
US15673T1007 - Common Stock
Taking everything into account, IPSC scores 3 out of 10 in our fundamental rating. IPSC was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability. IPSC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
IPSC had negative earnings in the past year.
IPSC had a negative operating cash flow in the past year.
IPSC had negative earnings in each of the past 5 years.
In the past 5 years IPSC reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -37.89%, IPSC is doing good in the industry, outperforming 63.25% of the companies in the same industry.
With a Return On Equity value of -73.97%, IPSC perfoms like the industry average, outperforming 54.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.89% | ||
| ROE | -73.97% | ||
| ROIC | N/A |
ROA(3y)-28.9%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IPSC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPSC has more shares outstanding than it did 1 year ago.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IPSC has an Altman-Z score of -2.30. This is a bad value and indicates that IPSC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.30, IPSC is in line with its industry, outperforming 47.69% of the companies in the same industry.
There is no outstanding debt for IPSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.3 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
A Current Ratio of 9.92 indicates that IPSC has no problem at all paying its short term obligations.
IPSC has a better Current ratio (9.92) than 80.17% of its industry peers.
A Quick Ratio of 9.92 indicates that IPSC has no problem at all paying its short term obligations.
The Quick ratio of IPSC (9.92) is better than 80.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.92 | ||
| Quick Ratio | 9.92 |
3. Growth
3.1 Past
IPSC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.44%.
Looking at the last year, IPSC shows a very negative growth in Revenue. The Revenue has decreased by -56.96% in the last year.
EPS 1Y (TTM)-0.44%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-18.18%
Revenue 1Y (TTM)-56.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-48.46%
3.2 Future
Based on estimates for the next years, IPSC will show a small growth in Earnings Per Share. The EPS will grow by 7.41% on average per year.
Based on estimates for the next years, IPSC will show a very strong growth in Revenue. The Revenue will grow by 87.80% on average per year.
EPS Next Y6.3%
EPS Next 2Y5.9%
EPS Next 3Y4.48%
EPS Next 5Y7.41%
Revenue Next Year57.26%
Revenue Next 2Y127.42%
Revenue Next 3Y58.56%
Revenue Next 5Y87.8%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPSC. In the last year negative earnings were reported.
Also next year IPSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.9%
EPS Next 3Y4.48%
5. Dividend
5.1 Amount
IPSC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CENTURY THERAPEUTICS INC
NASDAQ:IPSC (5/6/2024, 10:15:20 AM)
3.09
+0.06 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap256.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.89% | ||
| ROE | -73.97% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.92 | ||
| Quick Ratio | 9.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-0.44%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y6.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-56.96%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y